Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)

ABSTRACT Background The treatment of levodopa‐induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy. Objective The purpose of this study was to investigate the efficacy and safety of 274 mg ADS‐5102 (amantadine) extended‐release capsules (equivalent to 34...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Movement disorders 2017-12, Vol.32 (12), p.1701-1709
Hauptverfasser:	Oertel, Wolfgang, Eggert, Karla, Pahwa, Rajesh, Tanner, Caroline M., Hauser, Robert A., Trenkwalder, Claudia, Ehret, Reinhard, Azulay, Jean Philippe, Isaacson, Stuart, Felt, Larissa, Stempien, Mary Jean
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Amantadine Amantadine - therapeutic use Antiparkinson Agents - adverse effects Antiparkinson Agents - therapeutic use Appetite loss Confidence intervals Constipation Delayed-Action Preparations - therapeutic use Double-Blind Method Drug therapy Dyskinesia Dyskinesia, Drug-Induced - drug therapy Dyskinesia, Drug-Induced - etiology Female Hallucinations Humans Hypotension Levodopa Levodopa - adverse effects levodopa‐induced dyskinesia Male Middle Aged Movement disorders Nausea Neurodegenerative diseases Parkinson Disease - drug therapy Parkinson's disease randomized controlled trial Retrospective Studies Severity of Illness Index Sleep disorders Time Factors Treatment Outcome Unified Dyskinesia Rating Scale
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!